CAR T-cells in relapsed Burkitt lymphoma – a promising test drive in a rare disease: Leukemia & Lymphoma: Vol 63, No 10

206

Views

CrossRef citations to date

Altmetric

"CAR T-cells in relapsed Burkitt lymphoma – a promising test drive in a rare disease." Leukemia & Lymphoma, 63(10), pp. 2263–2264

Disclosure statement

J. Erika Haydu has no conflicts of interest. Jeremy Abramson declares the following relevant conflicts of interest: Bristol-Myers Squibb, Kite Pharma, AbbVie, Genentech, Genmab, Regeneron, Mustang Bio, Century Therapeutics

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

CAR T-cells in relapsed Burkitt lymphoma – a promising test drive in a rare disease

Information for

Open access

Opportunities

Help and information

CAR T-cells in relapsed Burkitt lymphoma – a promising test drive in a rare disease

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature